Arovella Therapeutics (ASX:ALA) has successfully manufactured and passed quality release testing for its lead product ALA-101 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240102/pdf/05z33l2t26k412.pdf #ALA #Cancer
FRS
0.026
160%
OCT
0.045
-42.3%
CRS
0.062
138.5%
NRZ
0.002
-33.3%
AVE
0.007
133.3%
CHM
0.006
-25%
LAT
0.074
111.4%
JAV
0.003
-25%
RLL
0.004
100%
HYD
0.019
-24%
SCN
0.027
80%
DUN
0.033
-23.3%
BP8
0.005
66.7%
TFL
0.01
-23.1%
EVR
0.005
66.7%
EXR
0.034
-22.7%
RGL
0.005
66.7%
GLL
0.007
-22.2%
SLM
0.105
66.7%
OZM
0.125
-21.9%
RR1
0.013
62.5%
TMG
0.036
-21.7%
RAS
0.025
56.3%
AGH
0.02
-20%
BGE
0.03
50%
CRR
0.004
-20%
CDT
0.003
50%
EM2
0.008
-20%
TMK
0.003
50%
CVL
1.06
-19.4%
BSX
0.051
45.7%
NWM
0.013
-18.8%
VIT
0.112
41.8%
AQD
0.04
-18.4%
CMO
0.024
41.2%
BUS
0.155
-18.4%
TOR
0.1
40.8%
LOT
0.195
-17%
EXT
0.018
38.5%
PUA
0.01
-16.7%
